within Pharmacolibrary.Drugs.ATC.S;

model S01LA09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.122 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 6 / 1000000,
    adminCount     = 1,
    Vd             = 0.00385,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Faricimab is a bispecific monoclonal antibody designed to bind and inhibit both angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). It is used for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab was approved by the US FDA in 2022 and is currently in clinical use.</p><h4>Pharmacokinetics</h4><p>PK parameters reported in patients with neovascular age-related macular degeneration (nAMD) receiving a 6 mg intravitreal dose.</p><h4>References</h4><ol><li><p>Diack, C, Gibiansky, L, Jaminion, F, Gibiansky, E, Gaudreault, J, Bogman, K, &amp; Cosson, V (2024). Ocular Pharmacokinetics of Faricimab Following Intravitreal Administration in Patients With Retinal Disease. <i>Translational vision science &amp; technology</i> 13(11) 14–None. DOI:<a href=&quot;https://doi.org/10.1167/tvst.13.11.14&quot;>10.1167/tvst.13.11.14</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39535744/&quot;>https://pubmed.ncbi.nlm.nih.gov/39535744</a></p></li><li><p>Agostini, H, Abreu, F, Baumal, CR, Chang, DS, G Csaky, K, Demetriades, AM, Kodjikian, L, Lim, JI, Margaron, P, Monés, JM, Peto, T, Ricci, F, Rüth, M, Singh, RP, Stoilov, I, Swaminathan, B, Willis, JR, &amp; Westenskow, PD (2024). Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. <i>Graefe&#x27;s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie</i> 262(11) 3437–3451. DOI:<a href=&quot;https://doi.org/10.1007/s00417-024-06531-9&quot;>10.1007/s00417-024-06531-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38847896/&quot;>https://pubmed.ncbi.nlm.nih.gov/38847896</a></p></li><li><p>Diack, C, Avery, RL, Cheung, CMG, Csaky, KG, Gibiansky, L, Jaminion, F, Gibiansky, E, Sickert, D, Stoilov, I, Cosson, V, &amp; Bogman, K (2024). Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema. <i>Translational vision science &amp; technology</i> 13(11) 13–None. DOI:<a href=&quot;https://doi.org/10.1167/tvst.13.11.13&quot;>10.1167/tvst.13.11.13</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39535745/&quot;>https://pubmed.ncbi.nlm.nih.gov/39535745</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01LA09;
